the Program - Simposio Científico SOGUG

Transcripción

V
SIMPOSIO CIENTÍFICO SOGUG
5th SCIENTIFIC MEETING SOGUG
Madrid
19 al 21 de Noviembre 2014 | 19th to 21st November 2014
Comité Científico | Scientific Committee
Dr. Javier Cassinello
Dr. Daniel Castellano
Dr. Miguel Ángel Climent
Dr. Ignacio Durán
Dra. Aránzazu González del Alba
Organizado por | Organized by
Dr. Luis León
Dra. Marta López-Brea
Dra. Mª José Méndez-Vidal
Dr. Juan Fco. Rodríguez-Moreno
Sede | Venue
Casino de Madrid
C/ Alcalá, 15, Madrid
Telf.: 91 521 87 00
MIÉRCOLES 19 NOVIEMBRE
WEDNESDAY 19th NOVEMBER
18:30 - 20:30
Encuentro con el Profesor | Meeting with the Professor
a enfermedad ósea en el cáncer de próstata | Bone disease in
L
prostate cancer
Dr. Dominik Berthold, CHUV, Lausanne, Switzeland
Auspiciado por Bayer | Sponsored by Bayer
Sede: Casino de Madrid | Venue: Casino de Madrid
Plazas limitadas. Se adjudicarán por riguroso orden de inscripción
| Limited places. Previous
registration is mandatory
20:30 - 21:45 Simposio Satélite - Janssen | Satellite Symposium - Janssen
Para asistir contacte con el Patrocinador | To attend, please contact the Sponsor
JUEVES 20 NOVIEMBRE
THURSDAY 20th NOVEMBER
08:15 - 09:15
Grupo “Young SOGUG” 1 “Young SOGUG” Group
08:15 - 08:30
Presentación del Proyecto “Young SOGUG”
Presentation of the “Young SOGUG” Project
Dr. Juan Fco. Rodríguez-Moreno, Hospital Madrid Norte Sanchinarro, Madrid
08:30 - 08:40
na carrera de investigación clínica fuera de España: formación en centros de
U
excelencia en EEUU | A clinical research career abroad: training at centres of
excellence in the USA
Dr. Carlos Álvarez Fernández, Hospital Central de Asturias, Oviedo
08:40 - 08:55
Primeros
pasos en investigación clínica. Becas: ¿cuáles, cuándo y cómo
solicitarlas? | First steps in clinical research. Grants: which ones, when
and how to apply for
Dra. Elena Castro, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid
08:55 - 09:15
Discusión y preguntas | Q&A
Dr. Álvaro Montesa, Hospital Universitario Carlos Haya, Málaga
09:30 - 10:25
Inmunoterapia
como estrategia de tratamiento en los tumores
genitourinarios | Immunotherapy as a strategy of treatment of
genitourinary tumours
Moderadores | Chairpersons
Dr. José Ángel Arranz, Hospital Universitario Gregorio Marañón, Madrid
Dr. Francisco Zambrana, Hospital Infanta Sofía, Madrid
09:30 - 09:50
Inmunoterapia para no inmunólogos | Immunotherapy for non-immunologists
Dr. Larry Fong, USCF Medical Centre, San Francisco, USA
09:50 - 10:10
Inmunoterapia en tumores urológicos | Immunotherapy in urological tumours
Dr. Tom Powles, Barts Cancer Institute, London, UK
10:10 - 10:25
Discusión | Discussion
JUEVES 20 NOVIEMBRE
10:30 - 12:30
Talleres | Workshops
1.Vacunas para el tratamiento de cáncer de próstata | Vaccines for the
treatment of prostate cancer
Dr. Larry Fong, USCF Medical Centre, San Francisco, USA
2.Inmunoterapia en cáncer renal y futuro de las combinaciones con TKI
Immunotherapy in renal cancer and the future of combinations with TKI
Dr. José Luis Pérez Gracia, Clínica Universitaria de Navarra, Pamplona
3.Inmunoterapia en cáncer de vejiga. Perspectivas y nuevos horizontes
Immunotherapy in bladder cancer. Perspectives and new horizons
Dr. Tom Powles, Barts Cancer Institute, London, UK
Los tres talleres se realizarán simultáneamente en dos sesiones consecutivas.
The three workshops will be held simultaneously in two consecutive sessions.
Previous registration is mandatory
12:30 - 13:30
Concurso de casos clínicos | Clinical vignettes contest
Dr. Javier Cassinello, Hospital General Universitario, Guadalajara
Dra. Marta López-Brea, Hospital Marqués de Valdecilla, Santander
Dr. Juan Fco. Rodríguez-Moreno, Hospital Madrid Norte Sanchinarro, Madrid
13:30 - 15:15
Simposio de industria - Astellas | Industry workshop - Astellas
Para asistir contacte con el Patrocinador | To attend, please contact the Sponsor
JUEVES 20 NOVIEMBRE
15:15
INICIO SESIÓN DE TARDE | START OF AFTERNOON SESSION
15:15 - 16:45
Terapias
dirigidas a la vía del AR y el hueso | Therapies targeting
the androgen receptor pathway and the bone
Dr. Ignacio Durán, Hospital Universitario Virgen del Rocío, Sevilla
Dr. Joan Carles, Hospital General Universitari Vall d’Hebron, Barcelona
15:15 - 15:40
ecanismos de progresión en el cáncer de próstata resistente a la castración
M
Mechanisms for progression of castrate resistant prostate cancer
Dr. Enrique González Billalabeitia, Hospital General Universitario Morales Meseguer, Murcia
15:40 - 16:05
El andrógeno
y su receptor como diana de tratamiento | The androgen and
its receptor as a treatment target
Dr. Pablo Maroto, Hospital de la Santa Creu i Sant Pau, Barcelona
16:05 - 16:30
Actualizaciones
en tratamientos dirigidos al hueso y combinación con
otras estrategias terapéuticas | Update on therapies targeting the bone
and combination with other treatment strategies
Dr. Álvaro Pinto, Hospital Universitario La Paz, Madrid
16:30 - 16:45
16:45 - 17:15
Café | Coffee break
JUEVES 20 NOVIEMBRE
17:15 - 19:00
1. Discusión de 2 casos clínicos | Discussion of 2 clinical vignettes
-Tratamiento de secuenciación dirigido sólo al AR | Sequencing treatment
aiming only at AR
-Mecanismos de resistencia y subgrupo de pacientes sensibles a inhibidores de AR
Mechanisms of resistance and subgroup of patients sensible to AR inhibitors
Dr. Ignacio Durán, Hospital Universitario Virgen del Rocío, Sevilla
-Tratamientos de combinación futura en CPRC | Treatments of future combination
in CRPC
- Nuevas dianas terapéuticas en CPRC | New therapeutic targets in CRPC
Dr. Pablo Maroto, Hospital de la Santa Creu i Sant Pau, Barcelona
-Tratamiento dirigido sólo a metástasis óseas | Treatment targeting only bone
metastases
-Impacto de fármacos dirigidos al hueso en puntos con afectación de partes blandas
Impact of drugs targeting the bone with soft tissue parts
Dr. Álvaro Pinto, Hospital Universitario La Paz, Madrid
Los tres talleres se realizarán simultáneamente en dos sesiones consecutivas
VIERNES 21 NOVIEMBRE
FRIDAY 21st NOVEMBER
08:30 - 09:15
Asamblea General SOGUG | SOGUG General Assembly
09:30 - 11:00
Tratamiento
de quimioterapia en tumores GU | Chemotherapy
treatment in GU tumours
Dra. Begoña Mellado, Hospital Clínic, Barcelona
Dra. Aránzazu González del Alba, Hospital Universitari Son Espases, Palma de Mallorca
09:30 - 09:55
La integración de la quimioterapia en el carcinoma de próstata hormono-sensible
Integration of chemotherapy in hormone-sensitive prostate carcinoma
Dr. Ronald de Wit, Erasmus University Medical Center, Rotterdam, Holland
09:55 - 10:20
L a integración del tratamiento citotóxico en el CPRC | Integration of
cytotoxic treatment in CRPC
Dr. Miguel Ángel Climent, Instituto Valenciano de Oncología (IVO), Valencia
10:20 - 10:45
E l papel de la quimioterapia en el cáncer de vejiga | The role of chemotherapy
in bladder cancer
Dr. Joaquim Bellmunt, Dana-Farber, Brigham and Women’s Cancer Centre,
Harvard Univ., Boston, USA
10:45 - 11:00
11:15 - 13:00
-Paciente ideal para tratamiento de QT en el paciente hormono sensible | Ideal
patient for chemotherapy treatment in hormone-sensible patient
-Paciente ideal para tratamiento de QT en CPRC | Ideal patient for chemotherapy
treatment in CRPC
Dr. Ronald de Wit, Erasmus University Medical Center, Rotterdam, Holland
-Paciente unfit y nuevas propuestas de tratamiento | Unfit patient and new
treatment approaches
-Paciente tras fallo platino. Impacto de nuevas moléculas | Platinum failure patient.
Impact of new molecules
Dr. Joaquim Bellmunt, Dana-Farber, Brigham and Women’s Cancer Centre, Harvard Univ.,
Boston, USA
-Paciente TGNS de alto riesgo. Inadecuada respuesta de marcadores tumorales a QT
High risk NSGCT patient. Inadequate tumour marker response to chemotherapy
-Vigilancia activa en TG. Recomendaciones y normas de seguimiento | Active surveillance in GCT. Recommendations and standards for monitoring
Dr. Karim Fizazi, Institute Gustave-Roussy, Villejuif, France
Los tres talleres se realizarán simultáneamente en dos sesiones consecutivas.
15:30
INICIO SESIÓN DE TARDE | START OF AFTERNOON SESSION
15:30 - 17:00
Estado
de la investigación en tumores GU | Ongoing research in
GU tumours
Dr. Daniel Castellano, Hospital Universitario 12 de Octubre, Madrid
Dr. Jesús García-Donas, Centro Integral Oncológico Clara Campal (CIOCC), Madrid
15:30 - 16:00
Mecanismos
cell cancer
de resistencia en cáncer renal | Mechanisms of resistance in renal
Dr. Primo Lara, UC Davis Comprehensive Cancer Center, Sacramento, USA
16:00 - 16:30
ltas dosis de QT en tumores germinales: a qué pacientes y cómo | High dose
A
chemotherapy in germ cell cancer: to whom and how
Dra. Anja Lorch, UKD Universitätsklinikum, Düsseldorf, Germany
16:30 - 17:00
Conferencia
anual SOGUG: Tres décadas en la investigación clínica en
cáncer renal | SOGUG annual lecture: Three decades in renal cell cancer
clinical research
Dr. Daniel Castellano, Hospital Universitario 12 de Octubre, Madrid
17:00 - 17:30
Café | Coffee break
17:30 - 18:30
Talleres
| Workshops
Terapias dirigidas en cáncer renal y retos en la práctica clínica
Targeted therapies in renal cancer and challenges in clinical practice
1.Evaluación de la respuesta en el tratamiento con terapias dirigidas
Response evaluation when using targeted therapies
Dra. Mª José Méndez-Vidal, Hospital Universitario Reina Sofía, Córdoba
Dr. Roberto García-Figueiras, Complejo Hospitalario Universitario de Santiago (CHUS),
Santiago de Compostela
2.Secuenciación en cáncer renal: dos opciones para un mismo problema
(TKI-TKI) | Sequencing in renal cancer: two options for the same
problem (TKI-TKI)
Dr. Javier Puente, Hospital Clínico Universitario San Carlos, Madrid
3.
Secuenciación en cáncer renal: dos opciones para un mismo problema
(TKI-mTOR) | Sequencing in renal cancer: two options for the same problem (TKI-mTOR)
Dr. Viktor Grünwald, Hannover Medical School, Hannover, Germany
Talleres simultáneos.
The three workshops will be held simultaneously.
18:30
Clausura | Closing remarks
Dr. Daniel Castellano, Presidente de SOGUG
Participantes
Participants
Ponentes y Moderadores | Speakers & Chairpersons
PARTICIPANTES
PARTICIPANTS
Dr. Carlos Álvarez Fernández
Hospital Central de Asturias, Oviedo
FORMACIÓN ACADÉMICA
• Diplomatura en Enfermería, Sept 99 - Jun 02. E.U. de Enfermería, Universidad de Oviedo, Asturias.
• Licenciatura en Medicina, Sept 02 - Jun 08. Facultad de Medicina, Universidad de Oviedo, Asturias.
Examen de Grado de Licenciatura, con calificación de Notable.
• Especialista en Oncología Médica, M.I.R. May 09 - May 13. Hospital Universitario Central de
Asturias (HUCA), Oviedo, Asturias.
• Suficiencia investigadora, Jun 12, “Valor predictivo de la expresión de reduced folate carrier (RFC) en
el tratamiento del cáncer de pulmón no microcítico (CPNM) avanzado con pemetrexed”.
• Máster Universitario en Investigación en Cáncer, Jun 12. Universidad de Oviedo - Instituto
Universitario de Oncología del Principado de Asturias (IUOPA), Asturias.
• Diploma de Postgrado en Oncología Médica – S.E.O.M., Curso 10 - 12. Universidad de Girona –
Sociedad Española de Oncología Médica.
EXPERIENCIA LABORAL
• Enfermero. Centro Comunitario de Sangre y Tejidos de Asturias. Jun 02 - May 08.
• M.I.R. Oncología Médica. Hospital Universitario Central de Asturias. Servicio de Salud del
Principado de Asturias (SESPA). May 09 - May 13.
(Estancia Formativa en MD Anderson Cancer Center Madrid España. Feb 12)
• Oncólogo médico (F.E.A.). Hospital Universitario Central de Asturias. Servicio de Salud del
Principado de Asturias (SESPA). Jun 13 - Mar 14.
• Oncólogo médico (Visiting Physician). University of California, San Francisco. Helen Diller Family
Comprehensive Cancer Center. Department of Hematology /Oncology, Genitourinary Tumors
Program. - Beca del grupo SOGUG - Abr 14 - Jun 14.
Varias publicaciones como primer firmante y como segundo y siguientes firmantes.
Varias comunicaciones en Congresos como primer firmante y como segundo y siguientes firmantes.
MIEMBRO DE COMISIONES Y SOCIEDADES CIENTÍFICAS
Comisión de Docencia (Julio 2011 - Mayo 2013. H.U.C.A). Comisión de Tumores (Ene 12 - May13.
H.U.C.A.). Grupo Español de Oncología Genitourinaria (S.O.G.U.G.). Sociedad Española de
Oncología Médica (S.E.O.M.). European Society for Medical Oncology (E.S.M.O.). American Society
of Clinical Oncology (A.S.C.O.)
OTROS MÉRITOS
Colaborador de Honor del Departamento de Medicina de la Universidad de Oviedo.
Cursos 2011/12, 2012/13 y 2013/14.
PARTICIPANTES
PARTICIPANTS
Dr. José Ángel Arranz
Hospital Universitario Gregorio Marañón, Madrid
- Licenciado en Medicina y Cirugía (Universidad de Valladolid, 1985).
- Especialista en Oncología Médica (Hospital General Universitario Gregorio Marañón, 1990).
-Miembro del Comité de Expertos en Tumores Urológicos de la Consejería de Salud de la
Comunidad Autónoma de Madrid (1993).
- Diplomatura en Informática y Estadística (Universidad Autónoma de Barcelona, 1994).
-Jefe de Sección del Servicio de Oncología Médica del Hospital General Universitario
Gregorio Marañón (desde 2007 hasta la actualidad), y responsable de la “Unidad de
Tumores Urológicos y Ginecológicos” en dicho centro.
Dr. Joaquim Bellmunt
Dana-Farber, Brigham and Women’s Cancer Centre, Harvard Univ., Boston, USA
Dr. Joaquim Bellmunt is Associate Professor of Medicine at Harvard Medical School and
Attending Physician of Solid Tumor Oncology at Dana-Farber Cancer Institute (DFCI). He
also serves as the Director of the Bladder Cancer Center at DFCI and Dana-Farber/Brigham
and Women’s Cancer Center, Harvard University, Boston working as part of a multidisciplinary team to provide complete care for patients with genitourinary malignancies. He is
past chairman of the Committee of Advanced Bladder Cancer in the European Organization
for Research and Treatment of Cancer (EORTC) Genitourinary Group (EORTC-GU). He
is co-founder and has been President of the Spanish Group for Treatment of Genitourinary Tumors (SOGUG). Dr. Bellmunt’s efforts have largely centered on improving the care
of patients with genitourinary malignancies focusing on bladder and renal cell carcinoma.
His areas of interest in genitourinary oncology include the development of drugs directed to
novel therapeutic targets and early clinical and translational research in the field of growth factor receptors and angiogenesis. While his research interests are focused on bladder cancer, he
has extensive experience treating prostate, penile and kidney cancer. He serves on International committees focused on improving the treatments of genitourinary and bladder cancers. He
is a member of the Editorial Board of the Journal of Clinical Oncology and European Urology.
He has been chairing two of the larger multicenter international trials of new drugs in the
treatment of bladder cancer, in one of them, leading to the establishment of a new drug for
bladder cancer patients. Dr. Bellmunt’s research focuses on clinical trials with aims to improve
the treatment of patients with advanced bladder (urothelial) tumors as well as the development of novel agents for this disease. Dr. Bellmunt is currently involved in collaborative efforts
with basic scientists to analyze clinical, tissue, and biomarkers to optimize the administration
of targeted therapeutic agents in bladder cancer.
PARTICIPANTES
PARTICIPANTS
Dr. Dominik Berthold
CHUV, Lausanne, Switzeland
He obtained his MD at the University of Bologna/Italy in 1998 with a thesis on therapeutic
cancer vaccine employing genetically engineered breast cancer cells. He did this specialty training in internal medicine and medical oncology in southern Switzerland (F. Cavalli). During his
fellowship from 2005-2007 at Princess Margaret Hospital (PMH) in Toronto, Canada, (mentor Dr. IF Tannock, MM Moore) he focused his clinical and research activity on genito-urinary
cancers and particularly on prostate cancer. Dr. Berthold currently heads a specialized prostate clinic at the University Hospital in Lausanne, Switzerland, based on high quality multidisciplinary care as well as clinical research. He is the medical responsible of the clinical trial
unit, a member of the ethic committee as well as a member of several professional societies
(ASCO, ESMO, ESO) and research networks in Switzerland and in Europe (SAKK, EORTC).
He is strongly committed to high quality care in oncology as well as to rigorous research in
genito-urinary cancer.
Dr. Joan Carles
Hospital General Universitari Vall d’Hebron, Barcelona
El Dr. Joan Carles es licenciado en Medicina y Cirugía por la Universidad Autónoma de Barcelona
(1987), obteniendo su doctorado en 1992. Completó su formación en la especialidad de Oncología
Médica en el Hospital Universitario Germans Trias i Pujol de Badalona y en 1996 recibió el Certificado
Europeo en Oncología Médica de Viena.
En 1991 se incorporó a la Unidad de Oncología Médica del Hospital de Terrassa y desde abril 1992
hasta septiembre 2008 trabajó como médico oncólogo en el Hospital del Mar de Barcelona. En
septiembre de 2008 se incorporó al Departamento de Oncología de Vall d’Hebron como Jefe de
la unidad de Genitourinario, sistema nervioso central, sarcoma y tumores de origen desconocido.
El Dr. Joan Carles es co-fundador y ex-vicepresidente de la Sociedad Española para el Tratamiento
de Cáncer Genitourinario (SOGUG), miembro de la Sociedad Española de Tumores de Cabeza y
Cuello (CTT), así como miembro del Grupo Español de Investigación en Sarcoma (GEIS). Es profesor
de Medicina en la Universidad Autónoma de Barcelona desde 1995 y coordinador del programa de
formación de Oncología Médica. El Dr. Carles ha sido autor de alrededor de más de 70 artículos y
más de 100 presentaciones en congresos y capítulos de libros.
Sus intereses de investigación son la oncología clínica genitourinaria, el sarcoma y principios de la
investigación traslacional y clínica de los polimorfismos genéticos, así como la angiogénesis, como
objetivos en la terapia del cáncer. También coordina los ensayos clínicos multicéntricos nacionales de
los nuevos medicamentos en el tratamiento de la próstata, el riñón y el cáncer de vejiga.
Además, el Dr. Carles es un miembro de la Sociedad Americana de Oncología Clínica (ASCO), miembro de la Sociedad Europea de Oncología Médica (ESMO) y miembro de la Asociación Española de
Oncología Médica (SEOM). Ha actuado como consultor en calidad de asesor para la preparación y
el desarrollo de las Directrices de Oncología para el gobierno de Catalunya (Oncoguies CatSalut).
PARTICIPANTES
PARTICIPANTS
Dr. Javier Cassinello Espinosa
Hospital General Universitario, Guadalajara
- Licenciado en Cirugía y Medicina por la Universidad Complutense de Madrid.
-
Grado de Licenciado y realización de 12 cursos de Doctorado por la Universidad
Complutense de Madrid y por la Universidad de Alcalá de Henares.
- Especialista en Oncología Médica. Residencia (MIR) efectuada en el Hospital 12 de Octubre
de Madrid en el Servicio de Oncología Médica -periodo 1986-1990-.
- Médico Adjunto de Oncología Médica en la Unidad de Oncología Médica del Hospital
Miguel Servet de Zaragoza -periodo 1992-1995-.
- Jefe de la Unidad de Oncología Médica del Hospital General Universitario de Guadalajara,
desde 1995 hasta la actualidad.
- Estancia como becado en el Dpto. de Ginecología / Medicina Interna del Hospital de Oulu
(Finlandia) en 1978.
- Beca SEOM: “Clinical Exchange Program”. UTM Anderson Cancer Center, Houston (Texas),
EEUU en 1992.
Experiencia en Investigación Clínica de 18 años.
Miembro de la Sociedad Española de Oncología Médica (SEOM), de la European Society of
Medical Oncology (ESMO) y de la American Society of Clinical Oncology (ASCO).
Dr. Daniel Castellano
Hospital Universitario 12 de Octubre, Madrid
Dr. Castellano is a Medical Oncologist of University Hospital 12 de Octubre (Madrid) with a
special interest in the diagnosis and treatment of genitourinary tumors such as renal, bladder,
prostate and testicular cancer.
He is currently Head of the GU Oncology Unit, Germ Cell Tumors Unit and Neuroendocrine
Tumors Unit.
His research is focused on the development of new drugs in GU tumors and Neuroendocrine
tumors, and he is the Principal Investigator of more than 15 clinical trials (phase I, II and
III trials). He has published more than 30 peer-review articles in relevant and recognized
oncology journals.
Dr. Castellano is Chair of Spanish Oncology Genitourinary Group (SOGUG), member of
executive committee of GETNE (Spanish Group of Neuroendocrine tumors), and member
of a different International and National Scientific organizations.
PARTICIPANTES
PARTICIPANTS
Dra. Elena Castro
Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid
Dr. Elena Castro received her MD from Universidad de Salamanca in 2003 and her PhD in
2010. She specialized in Medical Oncology at Hospital Uiversitario de Salmanca. After completing her residency training, she moved to London where she worked for four years as clinical
research fellow in cancer genetics and prostate cancer at the Insitute of Cancer Research & The
Royal Marsden Hospital. Dr. Castro moved back to Spain in January 2013 to the Prostate Cancer Unit at the Spanish National Cancer Research Centre (CNIO). Her research is focused on
populations with high risk of prostate cancer and on the clinical and molecular characterization
of prostate cancer tumors with DNA repair defects. She also works as honorary consultant in
Prostate Cancer at Centro Oncológico Integral Clara Campal.
Dr. Ignacio Durán
Hospital Universitario Virgen del Rocío, Sevilla
El Dr. Ignacio Durán trabaja en el Servicio de Oncología Médica del Hospital Universitario Virgen
del Rocío de Sevilla. Fue coordinador de docencia y del programa de tumores genitourinarios
del centro Integral Oncológico “Clara Campal” del Grupo Hospital de Madrid. Licenciado en
Medicina y Cirugía por la Universidad de Salamanca y Doctor por la Universidad Complutense
de Madrid. A lo largo de su carrera ha desarrollado estancias formativas en distintos centros
investigadores nacionales e internacionales tales como la sede del CSIC de la Universidad de
Salamanca, la Universidad Católica del Sacro Cuore de Roma (Italia), el “Centre Hospitalier
Universitaire” de Nantes (Francia) y el “Memorial Sloan Kettering Cancer Center” de Nueva
York (EE.UU).Tras su formación clínica en el Hospital Clínico Universitario de Son Dureta (Palma
de Mallorca), trabajó en el Servicio de Oncología Médica del Hospital Universitario Doce de
Octubre (Madrid) y durante el trienio 2004-2007 en los departamentos de Desarrollo de
Nuevos Fármacos y de Tumores Genitourinarios del “Princess Margaret Hospital” de Toronto
(Ontario, Canadá). Durante su estancia en Toronto completó un programa de Máster de
docencia orientada a la medicina en la Universidad de Toronto. Es autor de importantes trabajos
en diferentes ámbitos de la oncología médica publicados en destacadas revistas científicas. A
lo largo de su carrera ha recibido entre otros galardones, el ASCO Foundation Merit Award,
el Novartis Young Canadian Investigator Award y el University Health Network Outstanding
Research Presentation Award.
PARTICIPANTES
PARTICIPANTS
Dr. Karim Fizazi
Institute Gustave-Roussy, Villejuif, France
HOSPITAL AND LABORATORY APPOINTMENTS
September 2009: Full Professor, Institut Gustave Roussy, University of Paris, France.
Since June 2005: Appointed Head of the Department of Medicine, Institut Gustave Roussy (IGR),
France.
Since 2004: Chairman of the Genito-urinary Oncology Group, Institut Gustave Roussy (IGR),
France.
Since 2001: Assistant Professor in Medical Oncology, Department of Medicine, Institut
Gustave Roussy (IGR), France.
1999-2001: Visiting Assistant Professor, Genitourinary Medical Oncology Department, MD
Anderson cancer Center, Houston, TX, USA.
1997-1999: Assistant Professor in Medical Oncology, department of Medicine, Institut Gustave
Roussy (IGR), France.
1995-1997: Appointed Chef de clinique (Fellow) Medical oncology, Institut Gustave Roussy
(IGR), France.
1991-1995: Appointed Interne des hôpitaux de Paris (Residency):
- Medical Oncology, Department of Pr Marty, Hôpital St Louis (1995)
- Medical Oncology, Department of Pr Droz and Dr Le Chevalier, IGR (1995)
- Medical Oncology, Department of Pr Pouillart, Institut Curie (1993)
- Medical Oncology, Department of Pr Tursz, IGR (1993)
- Radiotherapy, Department of Pr Cosset, Institut Curie (1992)
- Medical Oncology, Department of Dr Ruffié, IGR (1992)
- Cardiology, Department of Pr Leca, Hôpital Laënnec (1991)
- Emergency, Department of Dr Duliouste, La Rochelle (1991)
1994: Diplôme d’Etudes Appliquées: Postgraduate Diploma prior to PhD, Fundamental Bases
of Oncogenesis, Pr Tursz’ Laboratory, IGR
MEDICAL AND SCIENTIFIC QUALIFICATIONS
2003: Ph.D. (Molecular Oncology)
1997: « Ancien Chef de Clinique » (Fellowship), Medical Oncology
1995: MD (Medical Oncology)
1990: Concours de l’Internat de Paris (Competitive Examination) ranked 45 / 3000 candidates,
Internal Medicine.
October 1984 to June 1990: Medical school, University of Poitiers, France
PARTICIPANTES
PARTICIPANTS
Dr. Lawrence Fong
USCF Medical Centre, San Francisco, USA
Lawrence Fong, M.D., is a Professor of Medicine in the Division of Hematology/Oncology at the University of California, San Francisco. He is focused on developing immune-based therapies for cancers
including prostate, kidney, melanoma, and colorectal cancers. He has been involved in pre-clinical and
clinical studies with sipuleucel-T and anti-CTLA4 antibodies. Dr. Fong currently leads a translational
immunotherapy program at UCSF and also leads a research lab studying antigen-specific recognition
of tumors in both mouse models and in patients. Current work includes developing biomarkers that
are associated with clinical responses or side effects. Dr. Fong obtained his MD at Stanford, completed internal medicine training at University of Washington, and oncology fellowship at Stanford. He
currently serves on multiple NIH study sections and committees including the NCI Investigational
Drug Steering Committee (IDSC), and NCI Genitourinary Cancers Steering Committee (GUSC).
He has served on the editorial board of the Journal of Clinical Oncology and currently serves as a
senior editor for Cancer Immunology Research, a new journal from AACR.
Dr. Jesús García-Donas
Centro Integral Oncológico Clara Campal (CIOCC), Madrid. Head of the Gynecological,
Genitourinary and Skin Cancer Unit. Director of the Familiar Cancer and Rare Tumors Program
Jesús García-Donas was born in Alcalá de Guadaira (Sevilla) in 1974. He received his MD from the
Universidad Complutense de Madrid in 1998 and subsequently trained as Medical Oncologist at the
Hospital Universitario Clínico San Carlos, Madrid. After completing his oncology training in 2002, Jesús
worked first in the Hospital Universitario de Elche. In 2003 later Jesús joined the Oncology Department of the Hospital Universitario Fundación Alcorcón, focusing in hereditary cancer syndromes and
gynecological, genitourinary tumors. In 2009, he completed his sub-specialization in Genitourinary
Tumors with a clinical fellowship at the New York Langone Medical Center under the supervision of
Dr. Ana Ferrari. Since May 2012 Jesús leads the Gynecological, Genitourinary and Skin Cancer Unit
and the Familiar and Rare Tumors Program at the Centro Integral Oncológico Clara Campal (Madrid).
Jesús has participated as co-investigator in up to 210 Phase I, II and III clinical trials and has published
over 20 papers in peer-reviewed journals, including the prestigious The Lancet Oncology and Journal
of Clinical Oncology.
Jesús currently leads several translational projects and clinical trials in the field of Kidney Cancer and
Rare Tumors. Most relevant are the EuroTarget study funded by the 7th Framework Program of the
European Union, that will deeply improve our knowledge of predictive biomarkers in renal tumors,
the CIRClEs study (Circulating Endothelial Cells in renal cancer) and the phase II study of dovitnib, a
new tyrosin kinase inhibitor, in adrenocortical carcinomas.
Jesús has also received several grants and awards including the 2006 FREMAP award for investigational
projects, the “Fundación Renal Iñigo Álvarez de Toledo” award, a grant for Independent Clinical Investigation from the Health Spanish Ministry (EC11-178) and a grant from the Instituto de Salud Carlos
III within the Acción Estratégica en Salud program.
PARTICIPANTES
PARTICIPANTS
Dr. Roberto García Figueiras
Complejo Hospitalario Universitario de Santiago (CHUS), Santiago de Compostela
Main Research Field
-Oncologic Imaging
-Abdominal/Pelvic Radiology
PhD in the field of FUNCTIONAL AND MOLECULAR IMAGING applied to Oncology
(2014): “Valor de las técnicas de imagen funcional y molecular en los tumores” (“The Value of
Functional and Molecular Imaging in Tumors”). Qualification: CUM LAUDE
- 6 books chapters published devoted to oncologic imaging
- 17 papers published devoted to oncologic imaging + other 34 radiological papers
- Speaker in many meetings mainly focused on oncologic imaging
- 12 national and international prizes in main radiological meetings
- International Meetings: 64 posters presented
- National Meetings: 53 posters presented
Dra. Aránzazu González del Alba
Hospital Universitari Son Espases, Palma de Mallorca
Dr. Aránzazu González del Alba Baamonde holds a Degree in Medicine and Surgery
from Madrid Autonomous University (1993).
She completed her training in Clinical Oncology in Son Dureta University Hospital (Palma de Mallorca, 1994-1997) and holds a Master in Molecular Oncology: Molecular bases
of Cancer. Molecular Pathology Program of the National Oncological Research Centre
(CNIO), recognized by the European School of Oncology (2007-2009).
She is a staff physician of the Department of Clinical Oncology of Son Espases Universitary Hospital and since 2002 she has directed the Unit of Urological and Gynecological
tumors.
Since 2009 she forms part of the Steering Committee of the Spanish Oncology Genitourinary Group (SOGUG), coordinating the Teaching Commission.
PARTICIPANTES
PARTICIPANTS
Dr. Viktor Grünwald
Hannover Medical School, Hannover, Germany
Dr. Viktor Grünwald is Professor for Oncology at the Medical School Hannover. Dr. Grünwald
received his medical degree from the Medical School Hannover in Hannover, Germany and
completed his doctorial and professorial thesis on topics of genitourinary cancers. He chairs the
tumor division of the center of rare disease at the Medical School Hannover. He is an author on
more than 100 scientific articles, abstracts and oncology book chapters. Dr. Grünwald reviewes
for several oncology journals.
Dr. Grünwald is an active member of the European Organisation for Research and Treatment
of Cancer (EORTC), American Society of Clinical Oncology (ASCO), and the European Society
for Medical Oncology (ESMO). He is board member of the German Medical Oncology studies
group (AIO) and of the Central European Society for Anticancer drug Research (CESAR). He
chairs the sarcoma group of the AIO and co-chairs the phase III unit of CESAR.
Dr. Grünwald is a member of the Scientific Committee of the ESMO (non-prostate genitourinary
committee), and for the German Society of Hematology and Oncology (DGHO). He acts as a
faculty member at the Flims Workshop on Methods in Clinical Research and the International
and European Kidney Cancer Symposium (I-KCS). Dr. Grünwald’s main focus is the development
of novel anticancer therapeutics, with a particular interest on kidney cancer, sarcomas, and head
and neck carcinomas. He participated in more than 70 clinical trials.
Dr. Primo N. Lara
UC Davis Comprehensive Cancer Center, Sacramento, USA
Dr. Lara is a clinician-scientist whose principal research interests are in the field of developmental
therapeutics, particularly in genitourinary and thoracic malignancies, as well as in cancer biomarker
development. He has a national and international reputation in clinical-translational research and
has chaired or co-chaired many cancer clinical trials from phase I to III. He directs an active clinical
practice in genitourinary and thoracic malignancies and is a strong advocate for cancer clinical trials.
Dr. Lara has received research funding from the National Institutes for Health/National Cancer
Institute (including R01 and R21 awards) and the American Cancer Society, among others. He has
authored or co-authored nearly 200 peer-reviewed manuscripts, most notably on novel or emerging anti-neoplastic strategies. He is currently principal investigator of the NCI-funded K12 Paul
Calabresi Clinical Oncology Training Grant, the NCI-funded N01 Early Therapeutics Award, and the
UC Davis ACS Institutional Research Grant. He also serves as an active co-investigator in several
NCI-funded drug development awards at UC Davis. Dr. Lara is active in medical education and
training, having served as chair of the American Society of Clinical Oncology’s Continuing Medical
Education Subcommittee in 2012-2013 and Education Committee chair of the International Association for the Study of Lung Cancer from 2011-2013. He has chaired SWOG’s Advanced Kidney
Cancer Organ Site since 2002, and serves as chair of SWOG’s Professional Review Committee.
PARTICIPANTES
PARTICIPANTS
Dra. Anja Lorch, MD
UKD Universitätsklinikum, Düsseldorf, Germany
Education and Career
1991-1993 Training as radiographer, University hospital Tübingen
1993-1994 Department of Radiooncology University hospital Tübingen
1994-2000 Medical school, Philipps-University, Marburg Medical clerkship in Chicago
(Northwestern University, USA)
2000-2002 Residency (AIP), department for hematology/oncology/immunology, (director:
Prof. Dr. A. Neubauer), University hospital, Marburg
2002-2007 Fellowship (Assistenzärztin), department for hematology, oncology and immunology, (director: Prof. Dr. A. Neubauer), University hospital, Marburg
2006 Conferral of a doctorate Philipps-University Marburg
2007 Consultant for internal medicine (Fachärztin für Innere Medizin)
2008 Consultant for hematology/oncology (Fachärztin für Hämatologie und Onkologie)
2008 ESMO exam (European Society for Medical Oncology)
2008 “Professor Dr. Adolph Schmidtmann-Stiftung” grant for an observership
at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York, USA (09-11/2008),
Department for urooncology
Since 2009 Attendant (Oberärztin), Department for hematology, oncology and immunology,
Philipps-University, Marburg (director: Prof. Dr. A. Neubauer)
May 2011 Habilitation and junior professor, Philipps-University Marburg. Theme: “Prognose
und Therapie rezidivierter Keimzelltumoren: Stellenwert der Hochdosischemotherapie“
2011 Observership at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York,
USA (09-11/2011), Department for urooncology
Since March 2012 Professor of Medical Oncology, Genitourinary Medical Oncology,
Heinrich-Heine University, Düsseldorf
Awards
2007 Wilsede Academy for Hematology and Oncology, “Hans-Jochen Illiger Gedächtnispreis
2007” (10 000 Euro)
Membership in Scientific Communities
Deutsche Gesellschaft für Hämatologie und Onkologie e.V. (DGHO). European Society for
Medical Oncology (ESMO). American Society of Clinical Oncology (ASCO). Interdisziplinäre
AG Hodentumoren. AG Urogenitaltumoren. Interdisziplinärer Arbeitskreis Uro-Onkologie
Marburg e.V.
PARTICIPANTES
PARTICIPANTS
Dr. Pablo Maroto Rey
Hospital de la Santa Creu i Sant Pau, Barcelona
Dr. Maroto is a medical oncologist working in the Sant Pau Hospital of Barcelona, Spain since 1999.
From his position, Dr. Maroto has been actively working in the uro-oncology arena participating
in more than 30 international clinical trials as principal investigator. He is member of different
collaborative groups, among them the Spanish Oncology Genito-Urinary Group (SOGUG)
where he has collaborated in the elaboration of Spanish Guidelines for the management of
prostate, kidney and bladder cancer. Besides, he presently is the Chairman of the Germ Cell
Cancer Group, the Spanish collaborative group for the treatment of Germ Cell cancer.
Dra. Begoña Mellado González
Hospital Clínic, Barcelona
Begoña Mellado González is a Consultant Medical Oncologist and co-Chair of the Urology
Cancer Unit at the Hospital Clínic i Provincial de Barcelona, Barcelona, Spain. She graduated in
Medicine from the University of Barcelona in 1989, completed her specialist training in Medical
Oncology at the Hospital Clínic i Provincial de Barcelona in 1993 and was awarded her PhD
by the University of Barcelona in 2002. She has also held research fellowship positions at the
Hospital Clínic i Provincial de Barcelona (1990–1994) and the Memorial Sloan-Kettering Cancer
Center (1995-1996).
Dr. Mellado is the elected Leader of the Prostate Cancer Group at the Translational Oncology
Research Laboratory, IDIBAPS, Hospital Clínic, University of Barcelona, and an active member
of the Prostate Cancer Group at the Spanish Genitourinary Oncology Group (SOGUG). Her
research focuses on urological cancer and translational research, particularly the detection
and characterization of circulating tumor cells in prostate cancer, and molecular mechanisms
of resistance to chemotherapy in castrate-resistant prostate cancer. She has authored or coauthored more than 50 peer-reviewed articles in these fields.
PARTICIPANTES
PARTICIPANTS
Dra. Mª José Méndez-Vidal
Hospital Universitario Reina Sofía, Córdoba
Dr. Méndez-Vidal is Associate Professor at Cordoba University and an active member of
the Spanish Oncology Genitourinary Group (SOGUG) and the Spanish Society of Medical
Oncology. Dr. Méndez-Vidal received her M.D. degree from the Universidad of Málaga. She
performed the Medical Oncology Residency at Clinical University Hospital in Córdoba, Spain.
She joined the staff at the Medical Oncology Service of University Hospital in Córdoba and
she is the Responsible of the Uro-oncological Unit. Her research interests are in Clinical GU
Oncology, with special attention to prostate and renal cancer.
Dr. Álvaro Montesa
Hospital Universitario Carlos Haya, Málaga
Licenciado en Medicina y Cirugía por la Universidad de Málaga en el año 2000 realizó la
residencia en Oncología Médica en el Hospital Carlos Haya de Málaga. Tras su paso por
los hospitales de Puerto Real de Cádiz y Virgen de las Nieves de Granada y una estancia
externa como observador en el Memorial Sloan Kettering Cancer Center, retornó al
Hospital Carlos Haya donde ejerce como adjunto especialista en el área de tumores
genitourinarios desde el año 2007, participando como investigador principal en varios
ensayos clínicos.
PARTICIPANTES
PARTICIPANTS
Dr. José Luis Pérez Gracia
Clínica Universitaria de Navarra, Pamplona
Especialista del Departamento de Oncología de la Clínica Universidad de Navarra.
Profesor titular de Medicina de la Universidad de Navarra, acreditado por la ANECA.
Vocal de la Junta Directiva del Grupo Español de Investigación en Tumores Urológicos (SOGUG).
Investigador principal en más de 60 ensayos clínicos y en 6 proyectos financiados en convocatorias competitivas.
Co-autor de más de 60 publicaciones indexadas y de 12 capítulos de libro
Revisor de 10 revistas especializadas. Miembro del Comité Editorial de PlosOne.
Dr. Álvaro Pinto
Hospital Universitario La Paz, – IdiPAZ, Madrid
- Licenciado en Medicina y Cirugía por la Universidad de Valladolid (2002)
-Médico Interno Residente de Oncología Médica en el Hospital Universitario La Paz, Madrid
(2003-2007)
-Médico Adjunto del Servicio de Oncología Médica, Hospital Universitario La Paz, Madrid
(2007 – actualidad). Responsable de la atención a pacientes con tumores urológicos
-
Doctor en Medicina por la Universidad Autónoma de Madrid, calificado sobresaliente
Cum Laude (2009)
-Investigador del Instituto de Investigación del Hospital La Paz (IdiPAZ), dentro del grupo de
Oncología Traslacional
-
Miembro de las siguientes sociedades científicas: ASCO, ESMO, SEOM, SOGUG,
Grupo Germinal
- Miembro del Grupo de Trabajo de Prevención del Cáncer y Diagnóstico Precoz de la SEOM
-
Participación como investigador principal o investigador colaborador en más de 40
ensayos clínicos
-Autor de artículos publicados en revistas de alto impacto del campo de la oncología (Journal
of Clinical Oncology, Cancer Treatment Reviews, European Journal of Cancer, Cancer and
Metastasis Reviews, Urologic Oncology, etc.)
- Autor de 16 capítulos en libros dentro del campo de la oncología
-Presentación de comunicaciones en congresos nacionales e internacionales (ASCO Annual
Meeting, ESMO Annual Meeting. ASCO Genitourinary Cancer Symposium, etc.)
PARTICIPANTES
PARTICIPANTS
Dr. Thomas Powles
Barts Cancer Institute, London, UK
Prof. Powles is the lead for Solid Tumors at Barts Cancer Institute. He leads a Translational
Oncology Group and is the Chief Investigator for 10 national and international studies. He
has written over 100 publications in the field of GU cancer and is on the faculty of a number
of international meetings including ESMO GU ASCO and ASCO in 2013.
Dr. Javier Puente
Hospital Clínico Universitario San Carlos, Madrid
Javier Puente es oncólogo médico en el Hospital Clínico San Carlos de Madrid, siendo uno de
los responsables de la Unidad de Tumores torácicos, urológicos y melanoma. Su labor asistencial se acompaña de una intensa actividad investigadora (como miembro del Grupo Español
de tumores genitourinarios (SOGUG) y del Grupo Español de Cáncer de Pulmón (GECP), así
como docente, siendo Profesor Asociado de Medicina en la Universidad Complutense de Madrid. Es además Asesor Técnico Nacional de la Asociación Española contra el Cáncer (AECC).
El Dr. Puente ha colaborado como autor en más de 50 artículos en revistas internacionales,
y ha sido nombrado recientemente Secretario Científico de la Sociedad Española de Oncología Médica (SEOM).
PARTICIPANTES
PARTICIPANTS
Dr. Juan Fco. Rodríguez-Moreno
Hospital Madrid Norte Sanchinarro, Madrid
Dr. Rodríguez is medical oncologist in the Department of Genitourinary & Gynecological tumors
and Coordinator of the Department of Skin Cancer of the Centro Integral Oncológico Clara
Campal (Comprehensive Cancer Center), Madrid (Spain). He participates as Clinical collaborator in the Prostate Cancer and Genitourinary Tumours Clinical Research Unit of the Spanish National Cancer Research Center (CNIO). Dr. Rodríguez is also
Associate Professor at the University CEU San Pablo and member of the Teaching Committee
of SOGUG.
Dr. Francisco Zambrana
Hospital Infanta Sofía, Madrid
University of Seville Medical School. Clinical Fellowship in Medical Oncology (Hospital Universitario Virgen Macarena, Seville. 2009). MPhil in tumor pathology (University of Seville, 2006).
Observership program at MD Anderson Cancer Center (Breast and Lymphoma Departments, 2008) and University Hospital (Palliative Medicine, University of Navarra, 2006). MPhil
in Oncology Research (Universidad San Pablo CEU & CIOCC, 2012). Observership program
at Hellen Diller Family Comprehensive Cancer Center (Genitourinary Center, 2014). Ongoing
clinical research in metabolomics (volatile organic compounds) and genomics for prediction
of response to chemoradiation. Areas of interest: cancer immunotherapy, GU, lung and head
& neck Oncology.
PARTICIPANTES
PARTICIPANTS
V
SIMPOSIO CIENTÍFICO SOGUG
5th SCIENTIFIC MEETING SOGUG
Madrid
19 al 21 de Noviembre 2014 | 19th to 21st November 2014
Sede | Venue
Casino de Madrid - C/ Alcalá, 15, Madrid - Telf.: 91 521 87 00
*Para acceder al Casino de Madrid es imprescindible el uso de chaqueta y corbata | Jacket and tie are required to access the conference venue
www. simposiocientificosogug.net
Patrocinadores | Sponsors
Colaboradores | Collaborators
Con el auspicio de | Under auspices of
18, cat. 1
ESMO-MORA
points
Solicitada acreditación a la Comisión de Formación
Continuada de las Profesiones Sanitarias de la Comunidad de Madrid | Accreditation by the Spanish System
of Continuing Medical Education requested
Technical Secretariat TACTICS MD - T. 93 451 17 24 - [email protected]

the Program - Simposio Científico SOGUG

Transcripción

Documentos relacionados